Recently, Director Wang Wei of the Department of Pathology of Pingshan Central Hospital and Director Sun Junzhong of the Department of Oncology visited Shenzhen Cell Valley for exchange and visit. Our chairman Shi Yuanyuan, comprehensive office director Wang Lu, research and development scientist Yang Yiqing and other people warmly received. Under the detailed introduction of Wang Lu, Director of the General Office, and Yang Yiqing, research and development scientist, the visiting leaders further understood the strategic positioning, founding team, corporate vision, development history, core technology advantages and four service platforms of Shenzhen Cell Valley. At the symposium, Chairman Shi Yuanyuan introduced that recently, the core technical team of Shenzhen Cell Valley cooperated with the high-level medical team of the city's public third-class hospitals. In Cell's multi-disciplinary JCR1 journal Heliyon, the first international case report of the clinical treatment of BCMA target CAR-T with retrovirus vector was published. This case relies on the preparation of retroviral vector, the core technology of Shenzhen Cell Valley, and the clinic-grade cell products produced show high performance, low cost and excellent transfection and in vivo expansion effects. The success of these clinical studies also indicates that the one-stop full-process service from basic research to clinical transformation advocated by Shenzhen Cell Valley has been recognized by doctors.
Director Sun Junzhong spoke highly of the progress of Shenzhen Cell Valley in the field of cell therapy, and introduced the situation of the Oncology Department of Pingshan Central Hospital. Afterwards, the two sides had an in-depth discussion on the application of retrovirus vectors in the field of tumor therapy and the doubts and difficulties faced by cell therapy. They also agreed that Shenzhen Cell Valley and Pingshan Central Hospital have a high degree of consistency and common vision in philosophy, and hope that the two sides can accelerate cooperation and bring new hope and treatment plans to cancer patients.